ASTRAZENECA PLC
AZN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AZN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AZN
AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in oncology, cardiovascular, respiratory, and other therapeutic areas. The company reported total revenue of $15.3 billion in Q1 2026 and held $9.8 billion in financial resources as of June 30, 2026.
Key risk: Pipeline failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$252.33B
Cash Runway
—
Lead Asset
Acalabrutinib (Phase 4)Next Catalyst
Phase3_Topline · Aug 31, 2026Financial data as of Dec 31, 2025.
Tracking 27 pipeline candidates · 589 clinical trials · 155 catalysts · 25 FDA decisions for ASTRAZENECA PLC.
AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in oncology, cardiovascular, respiratory, and other therapeutic areas. The company reported total revenue of $15.3 billion in Q1 2026 and held $9.8 billion in financial resources as of June 30, 2026.
- AstraZeneca reported total revenue of $15,288 million for Q1 2026, a 13% increase at actual exchange rates and 8% at constant exchange rates [sec · filed 2026-04-29].
- As of June 30, 2026, the Group had $9.8 billion in financial resources (cash and cash equivalents) [sec · filed 2026-07-27].
- The company has a deep pipeline with multiple Phase III readouts expected in late 2026, including for durvalumab, monalizumab, savolitinib, and AZD0901 [upcoming catalysts].
- AstraZeneca has a strong balance sheet with shareholders' equity of $39,166 million and total debt of $34,738 million as of December 31, 2025 [latest reported financials].
- The company is advancing several regulatory submissions, including for Enhertu in high-risk HER2+ early breast cancer and Calquence in 1L CLL [sec · filed 2026-04-29].
What works
- AstraZeneca has a robust pipeline with multiple positive Phase III data readouts in 2026, including Imfinzi in locoregional HCC and tozorakimab in COPD [sec · filed 2026-04-29].
- The company has a strong financial position with $9.8 billion in cash and equivalents as of June 30, 2026, supporting ongoing R&D and business development [sec · filed 2026-07-27].
- AstraZeneca is expanding its portfolio through strategic collaborations, such as the AI-driven peptide drug discovery deal with CSPC Pharmaceuticals [sec · filed 2026-07-27].
What to weigh
- AstraZeneca faces inherent risks of pipeline failures, as evidenced by the primary endpoint not being met in the SAMETA trial for Imfinzi+Orpathys in MET+ advanced papillary renal cell carcinoma [sec · filed 2026-04-29].
- The company is exposed to pricing, affordability, access, and competitive pressures that could impact commercial performance [sec · filed 2026-04-29].
- AstraZeneca's forward-looking statements are subject to risks including failure or delay in pipeline delivery, regulatory hurdles, and execution of commercial strategies [sec · filed 2026-07-27].
From the filings
Quoted directly from source documents.
The company has substantial financial resources.
“As at 30 June 2026, the Group has $ 9.8 bn in financial resources (cash and cash equivalent”
SEC filings · July 27, 2026
Catalyst timeline
- 2026-08-31 · Phase3_Topline — Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe — This trial evaluates a transarterial chemoembolization-based regimen; topline results will inform potential new treatment options in liver cancer.
- 2026-09-17 · Phase3_Topline · durvalumab — Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera — This study assesses durvalumab plus chemotherapy; topline data will clarify its efficacy in the indicated setting.
- 2026-09-24 · Phase3_Topline · monalizumab — Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati — This trial tests monalizumab versus placebo in combination with standard therapy; results will determine its potential as a new treatment option.
- 2026-09-30 · Phase3_Topline · durvalumab — Phase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line — This study evaluates durvalumab plus tremelimumab as first-line therapy; topline data will show efficacy and safety in this setting.
- 2026-10-14 · Phase3_Topline · azd0901 — Phase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa — This trial compares AZD0901 monotherapy to standard care; topline results will indicate its potential as a novel therapeutic option.
- 2026-10-30 · Phase1_Start — Phase 1 Start: A Multicentre, Randomised, Open-label, Phase I Study to Characterise the Pharmacokinetics, Pharmacod — This Phase I study will characterize pharmacokinetics and pharmacodynamics of a new candidate, marking the entry of a novel asset into clinical development.
- 2026-11-06 · Phase3_Topline — Phase 3 Topline: A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a — This placebo-controlled Phase III trial will evaluate efficacy and safety; topline data will inform regulatory and clinical decisions.
- 2026-11-23 · Phase3_Topline · savolitinib — Phase 3 Topline: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Plat — This study tests savolitinib plus osimertinib versus platinum-based therapy; topline results will assess the combination's benefit in the target indication.
Risks & what to watch (4)›
Key risks
- Pipeline failure risk — Failure or delay in delivery of pipeline or launch of new medicines could impact growth [sec · filed 2026-07-27].
- Regulatory and compliance risk — Failure to meet regulatory or ethical requirements for medicine development or approval [sec · filed 2026-07-27].
- Commercial execution risk — Failures or delays in the quality or execution of the Group's commercial strategies [sec · filed 2026-07-27].
- Pricing and access risk — Pricing, affordability, access and competitive pressures could affect revenue [sec · filed 2026-04-29].
What to watch
- Phase III topline results for durvalumab, monalizumab, savolitinib, and AZD0901 expected in late 2026 [upcoming catalysts].
- Regulatory decisions on key submissions such as Enhertu for high-risk HER2+ early breast cancer and Calquence for 1L CLL [sec · filed 2026-04-29].
- Progress of the strategic collaboration with CSPC Pharmaceuticals on AI-driven peptide drug discovery [sec · filed 2026-07-27].
- Impact of foreign exchange rates on 2026 financial performance, with a low single-digit positive impact anticipated [sec · filed 2026-04-29].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run ASTRAZENECA PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ASTRAZENECA PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.34
Lead: Approved
27 candidates
155 upcoming, next in ~1d
0 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,315
Total value held
$140.68B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 90,080,284 | $17.61B |
| investor ab | 51,587,810 | $10.17B |
| fmr llc | 29,601,724 | $5.80B |
| legal & general group plc | 25,849,978 | $5.01B |
| janus henderson group plc | 23,898,848 | $4.64B |
| wellington management group llp | 23,751,085 | $4.63B |
| bank of america corp /de/ | 19,058,327 | $3.76B |
| vanguard asset management, ltd | 18,535,315 | $3.62B |
| primecap management co/ca/ | 18,213,708 | $3.59B |
| franklin resources inc | 17,792,161 | $3.49B |
Showing top 10 of 1,315 institutional holders of ASTRAZENECA PLC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.1%
- Days to cover
- 0.9
- Shares short
- 1,830,898
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AZN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ASTRAZENECA PLC?
AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in oncology, cardiovascular, respiratory, and other therapeutic areas. The company reported total revenue of $15.3 billion in Q1 2026 and held $9.8 billion in financial resources as of June 30, 2026.
What is ASTRAZENECA PLC's lead drug candidate?
ASTRAZENECA PLC's most advanced tracked candidate is Acalabrutinib (Phase 4) for Phase I: Relapsed or Refractory B-cell Malignancies; Chronic Lymphocytic Leukemia (CLL); Untreated Chronic Lymphocytic Leukemia.
What is ASTRAZENECA PLC's next catalyst?
ASTRAZENECA PLC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe" — expected August 31, 2026.
Who is the CEO of ASTRAZENECA PLC?
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. is the chief executive officer of ASTRAZENECA PLC (AZN).
Where is ASTRAZENECA PLC headquartered?
ASTRAZENECA PLC (AZN) is headquartered in Cambridge, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.